quinoxalines has been researched along with alprostadil in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gnegy, ME; Mangels, LA | 1 |
| Carpéné, C; Galitzky, J; Lafontan, M; Saulnier-Blache, JS | 1 |
| Bouscarel, B; Ceryak, S; DeFabo, EC; Gettys, TW; Noonan, F; Phillips, TM | 1 |
| Gilbert, M; Laustsen, G; Wimett, L | 1 |
4 other study(ies) available for quinoxalines and alprostadil
| Article | Year |
|---|---|
Cyclic AMP accumulation alters calmodulin localization in SK-N-SH human neuroblastoma cells.
Topics: Adenylyl Cyclases; Adrenergic alpha-Agonists; Alprostadil; Analgesics; Brimonidine Tartrate; Bucladesine; Calcium; Calmodulin; Carbachol; Cell Line; Colforsin; Cyclic AMP; Cytosol; Edetic Acid; Egtazic Acid; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Humans; Kinetics; Neuroblastoma; Quinoxalines; Tumor Cells, Cultured; Vasoactive Intestinal Peptide | 1992 |
Selective reduction of alpha 2-adrenergic responsiveness in hamster adipose tissue during prolonged starvation.
Topics: Adenosine Deaminase; Adipose Tissue; Adrenergic beta-Agonists; Alprostadil; Animals; Blood Proteins; Brimonidine Tartrate; Cells, Cultured; Clonidine; Cricetinae; Fatty Acids, Nonesterified; Lipolysis; Male; Mesocricetus; Phenylisopropyladenosine; Quinoxalines; Receptors, Adrenergic, beta; Reference Values; Starvation | 1990 |
Regulation of stimulated cyclic AMP synthesis by urocanic acid.
Topics: Adrenergic alpha-Agonists; Alprostadil; Animals; Brimonidine Tartrate; Cells, Cultured; Colon; Cricetinae; Cyclic AMP; Dinoprostone; Epinephrine; Fibroblasts; Histamine; HT29 Cells; Humans; Liver; Mesocricetus; Quinoxalines; Urocanic Acid | 1998 |
Drug approvals.
Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline | 2007 |